1. Introduction {#s0005}
===============

Inflammation is a response of organisms to the presence of pathogens and chemical or mechanical injury. Although it is a defense mechanism, the complex events and mediators in the uncontrolled inflammation reaction can induce or sustain a pathologic process involved in different diseases *e.g*. arthritis, atherosclerosis, allergy, the metabolic syndrome, sepsis and auto-immune diseases as well as cancer ([@bib17; @bib1]). Initiation and promotion of inflammatory processes require synthesis of effector proteins such as cell adhesion molecules (VCAM-1, ICAM-1), inducible enzymes (COX-2 and iNOS), chemokines (MCP-1, MIP-1α), cytokines and growth factors (tumor necrosis factor alpha (TNF-α), interleukins) ([@bib26; @bib10]). Thus, one strategy to block inflammation is to inhibit inflammatory mediators on the transcriptional level. Among the involved transcription factors, nuclear factor kappa B (NF-κB) plays a prominent role. Therefore, the NF-κB signaling pathway represents an established target for anti-inflammatory drug discovery ([@bib32; @bib11]). Besides synthetic compounds, several natural products have been identified to inhibit NF-κB ([@bib3; @bib4; @bib5; @bib11; @bib2]).

In Vietnam, traditional medicine has a long established history and plays an important role in the health care system. Vietnam׳s territory with an area of more than 3,30,000 square kilometers has a number of key ecosystems including a variety of marine and coastal habitats, wetland, and two important river deltas and is known as a hot spot of biodiversity covering more than 12,000 plant species ([@bib23]). Many of these plants have been used to treat diseases and traditional knowledge is still preserved. In 2009, Nguyen and You screened 87 plants used in Vietnamese traditional medicine for inhibitory activity on NF-κB activation and identified seven methanolic extracts as potential inhibitors of this pathway. In a continuing effort to rationalize and assess the activity of medicinal plants in Vietnam for inflammatory diseases, we conducted a screening of 17 plants which are listed in the textbook "Medicinal plants and animals in Vietnam ([@bib22])". Two of the plant extracts showed promising inhibitory activity on NF-κB activation: the dichloromethane extracts of *Oroxylum indicum* and *Chromolaena odorata*. In 2010, Siriwatanametanon et al. found that the ethyl acetate extract of *Oroxylum indicum* possesses NF-κB inhibitory activity; however, identification of the responsible compound(s) was not described.

2. Materials and methods {#s0010}
========================

2.1. Plant material {#s0015}
-------------------

The plant material used in this study was collected from different locations in the south of Vietnam between March and September 2010. The collected species were identified and authenticated by taxonomists from the Department of Pharmacognosy, Faculty of Pharmacy, University of Medicine and Pharmacy of HoChiMinh city. Voucher specimens of plants are deposited in the herbarium of the Pharmacognosy Department at University of Medicine and Pharmacy of HoChiMinh city ([Table 1](#t0005){ref-type="table"}). Additional samples of the stem bark of *Oroxylum indicum* were collected in CuChi (sample Oro-1), in the botanical garden of Faculty of Pharmacy (HoChiMinh city; sample Oro-2), while sample Oro-3 and Oro-4 were collected in BinhPhuoc. All plant samples were air-dried and finally ground to a fine powder before further processing.

2.2. Extraction {#s0020}
---------------

### 2.2.1. Preparation of extracts for screening {#s0025}

Finely ground plant material (5 g) was extracted with 50 mL dichloromethane by sonication for 10 min at room temperature. The plant material was recovered by filtration and the process was repeated three times with fresh solvent. The obtained solutions were combined and evaporated to dryness using a rotavapor to give dichloromethane extracts. The residual plant material was air-dried and subsequently extracted with methanol using the same procedure as described above to yield the corresponding methanol extracts. All dried extracts were dissolved in dimethyl sulfoxide (DMSO) prior to bioactivity evaluation.

### 2.2.2. Extraction of the stem bark of *Oroxylum indicum* for quantification purposes {#s0030}

Dried stem barks of *Oroxylum indicum* were cut into pieces and ground to a fine powder. The plant material (0.5 g) was extracted five times with 40 mL of methanol by sonication (15 min each, at ambient temperature) and then centrifuged at 3300 rpm for 7 min. Extracts were combined, evaporated under reduced pressure and subsequently re-dissolved in methanol, quantitatively transferred to a volumetric flask and adjusted to the final volume (10 mL) with methanol. Prior to injection, all solutions were filtered through cotton wool. Each sample solution was assayed in triplicate.

2.3. NF-κB activity and cell viability {#s0035}
--------------------------------------

HEK293/NF-κB-luc cells (Panomics, RC0014), a HEK293 cell line stably transfected with NF-κB luciferase reporter, were used to determine NF-κB activity and cell viability as previously described ([@bib36]). Briefly, cells were maintained at 37 °C and 5% CO~2~ atmosphere in Dulbecco׳s modified Eagle׳s medium (DMEM; Lonza, Basel, Switzerland) with 100 U/mL benzylpenicillin 100 μg/mL streptomycin, 2 mM glutamine, and 10% fetal bovine serum (FBS). Before seeding in 96-well plates, cells were stained for 1 h in serum-free medium supplemented with 2 μM Cell Tracker Green CMFDA (Invitrogen), a fluorescent probe that is retained inside living cells and thus can be used to monitor cell membrane integrity and cell viability ([@bib19; @bib31; @bib12; @bib36]). Cells were then plated in 96-well plates (4×10^4^ cells/well) in phenol red-free and FBS-free DMEM overnight. The following morning, cells were pretreated with the investigated samples, positive control (parthenolide, 10 or 5 µM; IC~50~ value: 1.5 µM, 95% CI 1.3--1.8 µM) or solvent vehicle (0.1% DMSO in culture medium) for 30 min and stimulated with 2 ng/mL TNF-α for 4 h. Afterwards, the cells were lysed with a luciferase lysis buffer (Promega; E1531) and the luminescence of the firefly luciferase and the fluorescence of the Cell Tracker Green CMFDA were measured with a Genios Pro plate reader (Tecan, Grödig, Austria). For quantification of NF-κB activity, the luciferase-derived signal from the NF-κB reporter was normalized by the fluorescence signal derived from Cell Tracker Green CMFDA to account for differences in the cell number. Potential differences in viable cell numbers were detected by comparison of the Cell Tracker Green CMFDA fluorescence of the solvent vehicle treated cells and cells treated with the investigated samples.

2.4. Statistical analyses {#s0040}
-------------------------

Nonlinear regression (with sigmoidal dose response) was used to calculate the IC~50~ values using GraphPad Prism^®^ 4.03 (GraphPad Software, Inc.). Statistical differences were compared with ANOVA with Tukey׳s post-hoc test. *P* values\<0.05 were considered to be significant.

2.5. Chromatography and NMR analysis {#s0045}
------------------------------------

Fast Centrifugal Partition Chromatography (FCPC) (Kromaton, France) was equipped with Gilson 302/803 C pump system model 302 (Villiers-la-Bel, France).

LC for quantification---LC-parameter: HP 1090 system (Agilent, Waldbronn, Germany) equipped with autosampler, DAD and column thermostat; stationary phase: Zorbax SB-C18 column (150×4.6 mm, 3.5 µm particle size); mobile phase: solvent A: H~2~O with 0.5% formic acid (v/v); solvent B: methanol; DAD: 275 nm, temp.: 40.0 °C; injection volume: 5 μL; flow: 0.3 mL/min; composition during run: start: 40% B; 37 min: 70% B; 50 min: 75% B; 51 min: 98% B; 60 min: stop; post-time: 10 min.

LC--MS---LC-parameter: HP 1100 system (Agilent, Waldbronn, Germany) was equipped with auto-sampler, DAD and column thermostat. MS-parameters: Esquire 3000^plus^ (Bruker Daltonics, Bremen, Germany); ESI, temperature: 350 °C; dry gas: 10.00 L/min; nebulizer 40 psi; full scan mode: *m*/*z* 100--1500.

NMR: 1D- and 2D-experiments were measured on a Bruker DRX 300 (Bruker Biospin Rheinstetten, Germany) operating at 300.13 MHz (^1^H) and 75.47 MHz (^13^C) at 300 K (chemical shifts *δ* in ppm, coupling constants *J* in Hz); NMR solvent: MeOH-*d*~4~ or DMSO-*d*~6~ with 0.03% TMS (Eurisotop Gif-Sur-Yvette, France), which was used as an internal standard.

2.6. Extraction, purification and identification of pure compounds from *Oroxylum indicum* {#s0050}
------------------------------------------------------------------------------------------

Dried stem barks of *Oroxylum indicum* (Oro-1) (100 g) were ground to a fine powder and extracted with 500 mL methanol at room temperature (10 times). After removal of the solvent under reduced pressure, the resulting crude extract (16.10 g) was suspended in 300 mL of H~2~O and successively extracted with petroleum ether (300 mL×4), ethyl acetate (300 mL×4) and water saturated *n-*BuOH (300 mL×4). The resulting extracts were concentrated under reduced pressure, to give petroleum ether (0.72 g), ethyl acetate (0.85 g), *n-*butanol (2.74 g) and water (11.24 g) extracts. The ethyl acetate extract (0.85 g) was subjected to silica gel (40--63 μm, Merck, Darmstadt, Germany; 100 g) column chromatography, using a CH~2~Cl~2~/MeOH gradient with increasing amounts of MeOH as mobile phase. The eluate was monitored by TLC and combined to 19 fractions (O.E1 -- O.E19). Fraction O.E3 (CH~2~Cl~2~/MeOH, 99.7: 0.3) was recrystallized in CH~2~Cl~2~ to yield compound **1** (37.62 mg). Fraction O.E7 (CH~2~Cl~2~/MeOH, 99.5: 0.5; 35.46 mg) was purified by Sephadex LH-20 column chromatography using MeOH as mobile phase, yielding 15.44 mg of compound **2**. Fraction O.E11 (CH~2~Cl~2~/MeOH, 97: 3; 91.24 mg) was rechromatographed by Sephadex LH-20 column chromatography using MeOH as mobile phase, yielding 8 fractions (OE.11.1 -- OE.11.8) and compound **3** in fraction O.E11.5 (31.25 mg). Compound **4** (4.69 mg) was obtained by separation of fraction OE.11.7 by Sephadex LH-20 column chromatography with MeOH as mobile phase.

Since the minor compounds of the ethyl acetate extract were also present in a higher amount in the *n-*butanol extract (verified by HPLC-MS-experiments), the isolation work was carried out using the *n-*butanol extract. The *n-*butanol extract was re-dissolved in methanol. The MeOH-soluble part was fractioned by Sephadex LH-20 column chromatography with MeOH as mobile phase to yield 10 fractions (OB.1--OB.10). Fraction OB.4 (338.60 mg) was purified by means of FCPC using a solvent mixture of chloroform, methanol, water (9.5:10:5, all v/v, lower phase:mobile phase) to yield compound **5** (26.68 mg) and compound **8** (13.59 mg). Subfraction OB.4.2 (28.70 mg) was further separated with Sephadex LH-20 column chromatography using a mixture of methanol and water (1+1, v/v) as mobile phase to obtain compound **10** (5.34 mg) and compound **7** (4.90 mg). The MeOH-insoluble part of the *n-*butanol extract was separated by FCPC using the solvent system ethyl acetate, ethylene glycol dimethyl ether and water (2:1:2, upper phase:mobile phase), yielding 11 fractions (OBI.1--OBI.11). Fraction OBI.2 (16.63 mg) and fraction OBI.5 (9.50 mg) were rechromatographed by Sephadex LH-20 column chromatography using a mixture of methanol and water (1:1, v/v) as mobile phase to afford compound **9** (8.91 mg) and compound **6** (3.55 mg), respectively ([Fig. 1](#f0005){ref-type="fig"}).

3. Results and discussions {#s0055}
==========================

3.1. NF-κB inhibitory activities of dichloromethane and methanol extracts of 17 Vietnamese medicinal plants {#s0060}
-----------------------------------------------------------------------------------------------------------

In a primary screen, 40 different extracts of 17 plants were analyzed for their potential to inhibit TNF-α induced NF-κB activation in HEK-293 cells at a concentration of 10 µg/mL. Results are presented in [Fig. 2](#f0010){ref-type="fig"}. Strongest inhibition of NF-κB activation was found for *Chromolaena odorata* (DCM extract of the leaves) and *Oroxylum indicum* (DCM extract of the stem bark). In contrast to a previous study ([@bib24]) dichloromethane and methanol extracts of *Smilax glabra* at a concentration of 10 µg/mL did not show any effect, whereas the dichloromethane extract of *Chromolaena odorata* (at 10 µg/mL) was found to abrogate activation of NF-κB to a higher degree as the positive control (at 10 µM). In the study of [@bib24] methanol extracts of both species exhibited some minor NF-κB inhibitory effects (\<25% at 30 µg/mL). The rather strong effect of the dichloromethane extract of *Chromolaena odorata* in comparison to that of the methanol extract might be due to lipophilic constituents extractable by means of apolar solvents but not or only to some extent by polar ones. This is consistent with a recent investigation which identified six fatty acids as well as scutellarein tetramethyl ether from *Chromolaena odorata* ([@bib35]) as inhibitors of NF-κB activation. Further differences in the obtained findings might be a result of discrepancies in preparation of extracts, the setup of the *in vitro* assay, the selected sample concentration, and varying contents of active substances in the plant raw material, depending on harvest time and other influences.

NFκB inhibitory effects of the ethyl acetate extract of *Oroxylum indicum* were already reported by [@bib30], but the active principles were not determined. In the present study the dichloromethane extract of *Oroxylum indicum* was investigated and identified also as an inhibitor of NF-κB activation. Thus, both dichloromethane and ethyl acetate extracts were subjected to further phytochemical analysis.

3.2. Isolation of single constituents from the active fraction of *Oroxylum indicum* {#s0065}
------------------------------------------------------------------------------------

[Fig. 3](#f0015){ref-type="fig"} shows HPLC-DAD chromatograms of dichloromethane and ethyl acetate extracts of the stem bark of *Oroxylum indicum*. Compounds **1**--**3** are the main constituents of both extracts, while compounds **4**--**8** were not present in the dichloromethane extract. Therefore, a large scale ethyl acetate extract was prepared. Since compounds **5**--**8** were found in higher amounts in the *n-*butanol extract, isolation of these compounds was conducted using the *n*-butanol extract. After several purification steps by means of silica gel column chromatography, gel-filtration chromatography and counter-current chromatography, four flavonoid aglyca (**1**--**4**) could be isolated from the ethyl acetate extract and six flavonoid glycosides from the *n-*butanol extract (**5**--**10**). ^1^H and ^13^C NMR, as well as the 2-D-NMR data of compounds **1**--**8** were compared to literature data and found to be in good agreement with reported values ([@bib20; @bib7; @bib37; @bib39]). Based on NMR data and molecular weight determined by HPLC-MS*,* compounds **9** and **10** were identified as two methyl ester derivatives of compounds **5** and **8**, respectively. ^13^C NMR data of compounds **9** and **10** are shown in [Supplementary information](#s0095){ref-type="sec"} together with the ^1^H NMR-spectra of compounds **1**--**4**. Structures of isolated compounds (**1**--**10**) are shown in [Fig. 1](#f0005){ref-type="fig"}.

3.3. Analysis of the NF-κB inhibitory effect of isolated compounds from *Oroxylum indicum* {#s0070}
------------------------------------------------------------------------------------------

Ten isolated compounds from the bark of *Oroxylum indicum* were analyzed in an NF-κB assay at a concentration of 30 µM. No decrease in cell viability within the used experimental setup could be observed. Interestingly, only the four flavonoid aglyca inhibited the NF-κB reporter gene transcription while the six flavonoid glycosides showed no significant activity ([Fig. 4](#f0020){ref-type="fig"}). The anti-inflammatory activity of compound **8**, baicalin, which is the glycoside of baicalein has been previously studied in several *in vivo* tests. Cytoprotective properties against injury to the liver caused by ischemia/reperfusion ([@bib15]) and neuroprotective effects against ischemic reperfusion injury in rats ([@bib38]) were reported to be related to inhibition of NF-κB. However, in an interleukin-1β (IL-1β) induced human retinal pigment epithelial cell line ([@bib21]), baicalin neither inhibited IL-1β-induced IL-6 and IL-8 protein and mRNA production, nor did this flavonoid inhibit activation of NF-κB. Herein, we conducted the NF-κB assay with baicalein and baicalin simultaneously to demonstrate clearly the difference in activity between the flavonoid aglycone and its glycoside derivative *in vitro*. The result showed that baicalein was active while its glycoside, baicalin, did not suppress NF-κB activity in the HEK293/NF-κB-luc cell system. The same phenomenon was also observed with the glycosides of chrysin and oroxylin A and their corresponding aglyca. The increase in polarity and molecular weight due to the sugar moiety which negatively influences the penetration of cell membranes could be one explanation for the loss of activity of the glycosides.

3.4. IC~50~ determination of the active flavonoids {#s0075}
--------------------------------------------------

In order to establish a preliminary structure-activity relationship and to assess the contribution of the four active flavonoids (hispidulin, baicalein, chrysin and oroxylin A) to the inhibitory effect on NF-κB activation of the *Oroxylum indicum* extract, IC~50~ values were determined. Oroxylin A was the most active substance (IC~50~=3.9 µM, 95% CI: 3.5--4.4 µM) while chrysin and hispidulin showed lower activity (IC~50~=7.2 µM, 95% CI: 6.0--8.8 µM, and 9.0 µM, 95% CI: 7.9--10.2 µM, respectively) in our cell based test system. Interestingly, baicalein revealed only a weak activity (IC~50~=28.1 µM, 95% CI: 24.6--32.0 µM) ([Fig. 5](#f0025){ref-type="fig"}). Baicalein, chrysin and oroxylin A are known for their anti-inflammatory effects attributed at least partially through the suppression of NF-κB activation ([@bib8; @bib13; @bib18; @bib28; @bib27]) but this is the first time hispidulin was found to inhibit NF-κB activation. The results suggest that the presence of a hydroxyl group at the position 6 of the A ring (baicalein) reduces the activity of the flavone while a methoxyl group or no substitution at position 6 of the A ring (oroxylin A, hispidulin, chrysin) leads to a better inhibitory activity. Hispidulin possesses a similar structure to oroxylin A except for one additional hydroxyl group at position 4′ of the B ring. This modification results in a decrease of the ability to suppress NF-κB activation. These results supplement studies by [@bib6] who described the significance of hydroxyl groups at position 5 and 7 of the A ring and at position 4′ of the B ring for the effect of flavonoids in inhibiting ICAM-1, NF-κB and AP-1 activities on respiratory epithelial cells. [@bib29] studied the relationship among chalcone, flavanone, flavone and isoflavone derivatives and their inhibitory effect on TNF-α-induced NF-κB activation in HCT116 human colon cancer cell and emphasized the importance of hydroxyl substituents at C-5 position of the A ring of flavones.

3.5. Quantification of the active flavonoids (hispidulin, baicalein, chrysin and oroxylin A) in extracts and plant materials {#s0080}
----------------------------------------------------------------------------------------------------------------------------

Since baicalein was thought to be responsible for the anti-inflammatory activity of *Oroxylum indicum*, but showed only a weak NF-κB activity in this study, quantification of four flavonoids (hispidulin, baicalein, chrysin and oroxylin A) in the active extracts and stem bark materials was performed to get an idea about the contribution of each compound to the inhibitory effect on TNF-α-induced NF-κB activation. Validation of the established HPLC-DAD method is presented in [Supplementary information](#s0095){ref-type="sec"}. In the dichloromethane extract, hispidulin could not be determined; the contents of baicalein, chrysin and oroxylin A were 13.43%, 1.72%, 8.56% (w/w), respectively. These compounds were more abundant in the ethyl acetate extract: hispidulin (2.00%), baicalein (15.96%), chrysin (3.40%) and oroxylin A (13.85%, w/w). In both extracts the content of baicalein was higher than that of oroxylin A; however, the IC~50~ value of baicalein (IC~50~=28.1 µM) is almost 7 times higher than that of oroxylin A (IC~50~=3.9 µM). Therefore, it can be assumed that the NF-κB inhibitory activity of the dichloromethane and the ethyl acetate extracts is more driven by oroxylin A, although synergistic effects can never be ruled out. We also analyzed the content of the active flavonoids in four different *Oroxylum indicum* stem bark samples. The results (see [Table 2](#t0010){ref-type="table"}) showed a strong variation in the different samples. In general, baicalein (0.13--0.45%) was the dominant flavonoid aglycone in the stem bark, followed by oroxylin A (0.09--0.14%).

*Oroxylum indicum* is used in many Asian countries; however, different parts of the plant are often used. The seeds of *Oroxylum indicum* are described in the Chinese Pharmacopeia ([@bib33]) while the stem bark is present in the Vietnamese Pharmacopoeia ([@bib34]). In the Ayurvedic system of medicine, the root bark is the officially used part of *Oroxylum indicum* ([@bib25]). Due to the popularity of this herbal medicine, several analytical procedures have been reported for the detection of flavonoids in different plant parts. Interestingly, hispidulin was not detected in the seeds ([@bib16]), while all four compounds (hispidulin, baicalein, chrysin and oroxylin A) were detected simultaneously in the root bark ([@bib39]). Among the quantified flavonoids, baicalein was the dominant flavonoid aglycone in all plant parts of *Oroxylum indicum*, 0.09--0.18% in the seeds ([@bib16]), 0.13--0.45% in the stem bark ([Table 2](#t0010){ref-type="table"}), and 0.67% in the roots ([@bib39]).

4. Conclusion {#s0085}
=============

Ethnopharmacological knowledge is a promising source for the selection of potential bioactive plant material. Among 17 Vietnamese plants used for the treatment of a variety of diseases associated with inflammation, the dichloromethane extracts of *Chromolaena odorata* and *Oroxylum indicum* proved to be promising inhibitors of the NF-κB pathway. A previous study identified fatty acids of *Chromolaena odorata* as inhibitors of NF-κB activation ([@bib35]) but since the main constituents of this plant ([@bib9]) are flavonoids, it might be necessary to consider a contribution of these compounds to the NF-κB inhibitory effect of this plant. Phytochemical studies of *Oroxylum indicum* bark led to the identification of four bioactive flavonoids (hispidulin, baicalein, chrysin, and oroxylin A). Baicalein and its glycoside, baicalin, are well known for their anti-inflammatory activity related to the inhibition of NF-κB activation. However, in this study, simultaneous testing with other constituents of *Oroxylum indicum*, baicalein showed a weak activity while baicalin was inactive, whereas other flavonoids *e.g.* oroxylin A seem to be more important in respect to the NF-κB inhibitory effect of *Oroxylum indicum* extracts. Altogether, the performed study supports the traditional use of some of the investigated species against inflammation by the found *in vitro* activity and identified the stem bark of *Oroxylum indicum* as a valuable source of flavonoids with an anti-inflammatory activity.

Appendix A. Supporting information {#s0095}
==================================

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.jep.2014.10.012](http://dx.doi.org/10.1016/j.jep.2014.10.012){#ir0005}.
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![Structures of compounds (**1--10**) isolated from the stem bark of *Oroxylum indicum*.](gr1){#f0005}

![Effect of plant extracts (10 µg/mL) on NF-κB activation in HEK-293/NF-κB-luc cells; negative control: cells were treated with solvent vehicle (DMSO, 0.1%) and stimulated with TNF-α (2 ng/mL); positive control: cells were treated with parthenolide (10 µM) and stimulated with TNF-α. AP=aerial part; R=roots; St=stems; L=leaves; R=roots; Se=seeds; Th=thorns. The first letters of genus and species name of each plant were used to abbreviate plant names; see [Table 1](#t0005){ref-type="table"} for full names. Data points represent mean±S.E.M.; *n*=3, ^\*^*p*\<0.05 (ANOVA/Tukey) compared with negative control.](gr2){#f0010}

![HPL chromatograms of (A) dichloromethane extract and (B) ethyl acetate extract monitored at wavelength of 275 nm; for HPLC conditions see [Section 2](#s0010){ref-type="sec"}. Compound assignment: 1---Oroxylin A; 2---Chrysin; 3---Baicalein; 4---Hispidulin; for other compounds see [Fig. 1](#f0005){ref-type="fig"}.](gr3){#f0015}

![Effect of isolated compounds (30 µM) on NF-κB activity in HEK-293/NF-κB-luc cells; negative control: cells were treated which solvent vehicle (DMSO, 0.1%) and stimulated with TNF-α; positive control: cells were treated with parthenolide (5 µM) and stimulated with TNF-α. For compound assignment see [Fig. 1](#f0005){ref-type="fig"}. Data points represent mean±S.E.M.; *n*=3, ^⁎^*p*\<0.05 (ANOVA/Tukey) compared with negative control.](gr4){#f0020}

![Dose--response curves and IC~50~ values of hispidulin, baicalein, chrysin and oroxylin A with respect to NF-κB activation.](gr5){#f0025}

###### 

Latin names, plant parts and traditional uses of selected plant species in the screening for NF-κB inhibitors.

  **Latin name**                                                                     **Family**         **Plant part**        **Voucher specimen**         **Traditional uses** ([@bib22])
  ---------------------------------------------------------------------------------- ------------------ --------------------- ---------------------------- ---------------------------------------------------------------------------------
  *Abutilon indicum* (L.) Sweet                                                      Malvaceae          Aerial part           DN101                        Treatment of fever, rheumatism, dysuria, carbuncle
  *Achyranthes aspera* L.                                                            Amaranthaceae      Root, aerial part     DN102                        Treatment of rheumatism, contusion, osteodynia, dysuria
  *Barleria lupulina* Lindl.                                                         Acanthaceae        Aerial part           DL101                        Treatment of snake-bites, bleeding wounds, rheumatism
  *Coptosapelta tomentosa* (Blume) Vahl.ex Heyne var. *dongnaiensis* (Pit.) Phamh.   Rubiaceae          Stem, root            KH081                        Treatment of bleeding wounds, contusion or used as a tonic
  *Dischidia rafflesiana* Wall.                                                      Asclepiadaceae     Pitcher-shaped leaf   PQ101                        Treatment of rheumatism, snake-bites, jaundice or used as a tonic
  *Drynaria quercifolia* (L.) J.Sm.                                                  Polipodiaceae      Rhizome               DN103                        Treatment of rheumatism, osteodynia, dentagia
  *Chromolaena odorata* (L.) syn.: *Eupatorium odoratum* L. King et Robinson         Asteraceae         Aerial part           LA103                        Treatment of diarrhea, rheumatism, burns, skin wounds
  *Ficus pumila* L.                                                                  Moraceae           Stem, leaf            BMT101                       Treatment of rheumatism
  *Gleditsia fera* (Lour.) Merr.                                                     Caesalpiniaceae    Thorn                                              Treatment of carbuncle, osteodynia
  *Ipomoea biloba* Forsk. syn.: *Ipomoea pes-carprae* (L.) Sweet                     Convolvulaceae     Aerial part           PT101                        Treatment of fever, rheumatism, edema, snake-bites
  *Justicia gendarussa* L. syn.: *Gendarussa vulgaris* Nees                          Acanthaceae        Aerial part           DL102                        Treatment of osteodynia, rheumatism, jaundice, hives
  *Leea rubra* Blume                                                                 Leeaceae           Root                  BT101                        Treatment of rheumatism
  *Momordica cochinchinensis* (Lour.) Spreng.                                        Cucurbitaceae      Seed                  DL103                        Treatment of carbuncle, contusion, swelling
  *Oroxylum indicum* (L.) Vent                                                       Bignoniaceae       Stem bark             Oro-1, Oro-2, Oro-3, Oro-4   Treatment of allergy, inflammation, jaundice
  *Parabarium micranthum* (Wall.) Pierre ex Spire                                    Apocynaceae        Stem                  DN104                        Treatment of rheumatism, osteodynia
  *Scoparia dulcis* L.                                                               Scrophulariaceae   Aerial part           DN105                        Treatment of diabetes, hypertension, sore throat, used as an antidote
  *Smilax glabra* Roxb.                                                              Smilacaceae        Rhizome               DN106                        Treatment of syphilis, acute and chronic nephritis, metal poisoning, rheumatism

###### 

Amount of individual flavonoids in the active extracts (DCM and EtOAc extracts) and stem bark materials of different *Oroxylum indicum* samples (Oro-1 to Oro-4). Values shown in w% of air-dried plant material and relative standard deviations are in parenthesis (*n*=3).

                  Hispidulin     Baicalein      Chrysin        Oroxylin A     Σ of flavonoids (%)
  --------------- -------------- -------------- -------------- -------------- ---------------------
  DCM extract     n.d            13.43%         1.72%          8.56%          23.71
  EtOAc extract   2.0%           15.96%         3.42%          13.83%         35.21
  Oro-1           n.d            0.13% (4.36)   0.04% (1.43)   0.14% (3.92)   0.31
  Oro-2           0.01% (4.50)   0.26% (4.87)   0.05% (4.28)   0.19% (2.86)   0.51
  Oro-3           0.02% (1.19)   0.22% (4.46)   0.07% (1.22)   0.10% (1.11)   0.41
  Oro-4           0.03% (1.89)   0.45% (3.32)   0.15% (5.01)   0.09% (4.74)   0.71
